This work was supported by a grant from the ‘Dutch Cancer Society’ to E.S.J.M. de Bont (3661).
Acute Myeloid Leukemia (AML) bone marrow biopsies at diagnosis display enhanced angiogenesis and increased VEGFA expression. In a xenograft mouse model it was described that availability of free VEGFA versus bound VEGFA is related to different vascular morphology. In this study we investigate the relationship between vascular morphology within AML bone marrow biopsies and AML derived VEGFA levels.
Vessel count and surface area (Chalkley count) were calculated in AML bone marrow biopsies at diagnosis (n = 32), at remission (n = 8) and Normal Bone Marrow (n = 32) using immunohistochemical staining for FVIII, CD31, CTIV, SMA and VEGFA. VEGFA protein levels were measured.
High vessel count was associated with an immature vessel status. Combining vessel count and Chalkley count different vessel morphology patterns were quantified within AML bone marrow biopsies. Three different subgroups could be distinguished. The subgroup (37.5% of the samples) exhibiting a high vessel count and vessels with predominantly large lumen (normal Chalkley count) was associated with high secreted VEGFA protein levels.
Different vasculature patterns are seen in AML bone marrow biopsies, defined by combining number and size of vessel. These quantified morphology patterns, combined with VEGFA levels, might be of value in the success of VEGF/VEGFR-signaling interference approaches.
A. Aguayo, E. Estey, H. Kantarjian, T. Mansouri, C. Gidel, M. Keating, F. Giles, Z. Estrov, B. Barlogie, M. Albitar, Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94, 3717–3721 (1999) PubMed
J.W. Baish, R.K. Jain, Fractals and cancer. Cancer Res. 60, 3683–3688 (2000) PubMed
J.C. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, D.C. Arthur, M.J. Pettenati, S.R. Patil, K.W. Rao, M.S. Watson, P.R. Koduru, J.O. Moore, R.M. Stone, R.J. Mayer, E.J. Feldman, F.R. Davey, C.A. Schiffer, R.A. Larson, C.D. Bloomfield, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer to leukemia group B (CALGB 8461). Blood 100, 4325–4336 (2002) PubMedCrossRef
H.J. de Jonge, E.S. de Bont, P.J. Valk, J.J. Schuringa, M. Kies, C.M. Woolthuis, R. Delwel, N.J. Veeger, E. Vellenga, B. Lowenberg, G. Huls, AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 114, 2869–2877 (2009) PubMedCrossRef
W.H. Dokter, L. Tuyt, S.J. Sierdsema, M.T. Esselink, E Vellenga, The spontaneous expression of interleukin-1β and interleukin-6 is associated with spontaneous expression of AP-1 and NF-κB transcription factor in acute myeloblastic leukemia cells. Leukemia (Baltimore) 9, 425–432 (1995)
W. Fiedler, R. Mesters, H. Tinnefeld, S. Loges, P. Staib, U. Duhrsen, M. Flasshove, O.G. Ottmann, W. Jung, F. Cavalli, R. Kuse, J. Thomalla, H. Serve, A.M. O'Farrell, M. Jacobs, N.M. Brega, P. Scigalla, D.K. Hossfeld, W.E. Berdel, A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102, 2763–2767 (2003) PubMedCrossRef
D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C.J. Harrison, K. Wheatley, A.K. Burnett, A.H. Goldstone, The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312–1320 (2001) PubMedCrossRef
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D.D. Hu-Lowe, D.R. Shalinsky, G. Thurston, G.D. Yancopoulos, D.M. McDonald, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35–52 (2004) PubMedCrossRef
J.E. Karp, I. Gojo, R. Pili, C.D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, J. Zwiebel, Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 10, 3577–3585 (2004) PubMedCrossRef
T. Padro, S. Ruiz, R. Bieker, H. Burger, M. Steins, J. Kienast, T. Buchner, W.E. Berdel, R.M. Mesters, Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95, 2637–2644 (2000) PubMed
M. Sie, E.S. de Bont, F.J. Scherpen, E.W. Hoving, W.F. den Dunnen, Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?, Neuropathol. Appl. Neurobiol. (2010)
P.B. Vermeulen, G. Gasparini, S.B. Fox, C. Colpaert, L.P. Marson, M. Gion, J.A. Belien, R.M. de Waal, E. Van Marck, E. Magnani, N. Weidner, A.L. Harris, L.Y. Dirix, Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38, 1564–1579 (2002) PubMedCrossRef
F. Yuan, Y. Chen, M. Dellian, N. Safabakhsh, N. Ferrara, R.K. Jain, Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996) PubMedCrossRef
- High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
Alida C. Weidenaar
Arja ter Elst
Wilfred F. A. den Dunnen
Tiny Meeuwsen-de Boer
Willem A. Kamps
Eveline S. J. M. de Bont
- Springer Netherlands